Edition:
India

Neptune Technologies & Bioressources Inc (NEPT.OQ)

NEPT.OQ on NASDAQ Stock Exchange Capital Market

2.61USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$2.61
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
95,956
52-wk High
$3.58
52-wk Low
$0.70

Latest Key Developments (Source: Significant Developments)

Neptune Technologies Announces Research Agreement Aimed At Medical Cannabinoid-Based Products
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Neptune Technologies & Bioressources Inc ::NEPTUNE ANNOUNCES RESEARCH AGREEMENT AIMED AT NEW MEDICAL AND WELLNESS CANNABINOID-BASED PRODUCTS.NEPTUNE TECHNOLOGIES & BIORESSOURCES-ANNOUNCED EXCLUSIVE RESEARCH AGREEMENT FOR DEVELOPING NEW MEDICAL, WELLNESS TARGETED CANNABINOID-BASED PRODUCTS​.NEPTUNE TECHNOLOGIES & BIORESSOURCES INC - ‍ REACHED THE EXCLUSIVE RESEARCH AGREEMENT WITH A KRILL OIL PROVIDER​.  Full Article

Neptune Technologies Extends Global Maxsimil Licence To Cannabis-Derived Products​
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Neptune Technologies & Bioressources Inc ::NEPTUNE TECHNOLOGIES & BIORESSOURCES - CO EXTENDS GLOBAL MAXSIMIL LICENCE TO CANNABIS-DERIVED PRODUCTS​.  Full Article

Neptune Q2 revenue C$6.8 million versus C$11.6 million
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Neptune Technologies & Bioressources Inc :Neptune announces second quarter results.Q2 revenue C$6.8 million versus C$11.6 million.Neptune Technologies & Bioressources Inc - ‍gain of $23.9 million realized from sale of Krill Oil business​.Neptune Technologies & Bioressources Inc - ‍net income was $20.0 million for quarter, versus a net loss of $0.7 million in prior year​.  Full Article

Neptune and Ingenutra signs exclusive worldwide agreement for MaxSimil
Friday, 7 Oct 2016 

Neptune Technologies & Bioressources Inc : Terms also cover potential collaboration between both companies on clinical trials . Neptune Technologies & Bioressources Inc says all other terms of agreement remain confidential . Neptune and Ingenutra sign an exclusive worldwide agreement for Maxsimil . All other terms of agreement remain confidential. . Agreement allows neptune to manufacture, distribute and sell Maxsimil in nutraceutical field worldwide .Says agreement is valid till 2028.  Full Article

Richard Schottenfeld reports 5.4 pct stake in Neptune Technologies & Bioressources
Saturday, 23 Jul 2016 

Neptune Technologies & Bioressources Inc : Richard Schottenfeld Reports 5.4 Pct Stake In Neptune Technologies & Bioressources Inc As Of July 12 - SEC filing .Acquired shares of Neptune Technologies common stock believing that such shares of common stock were undervalued.  Full Article

Neptune announces Q1 results
Tuesday, 12 Jul 2016 

Neptune Technologies & Bioressources Inc :Neptune announces first quarter results.  Full Article

Acasti posts qtrly loss per share of $0.29
Tuesday, 12 Jul 2016 

Acasti Pharma Inc: Acasti announces first quarter results .Qtrly loss per share $0.29.  Full Article

Neptune Technologies & Bioressources qtrly revenues $11.3 mln
Tuesday, 12 Jul 2016 

Neptune Technologies & Bioressources Inc : Neptune Technologies & Bioressources Inc qtrly revenues reached $11.3 million, up 270% versus last year . Revised revenue guidance for fiscal 2017 to over $43 million, continue to expect double-digit adjusted ebitda margin for 2017 . Qtrly loss per share $0.03 . Consolidated cash, short term investments were $14.6 million as at may 31, 2016, with $9.6 million for co's unit acasti .If acasti doesn't raise funds, exists material uncertainty that casts doubt about acasti’s ability to continue as going concern.  Full Article